Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: Comparison of rasagiline (TVP 1012) with selegiline

Journal of Neurology

Volumn 248, Issue 9, 2001, Pages 985-1009

  Kupsch, A ^a,b   Sautter, J ^a   Gotz M E ^c   Breithaupt, W ^c   Schwarz, J ^a,e   Youdim, M B H ^d   Riederer, P ^c   Gerlach, M ^c   Oertel, W H ^a,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

A and B; Common marmoset; Monoamine oxidase; MPP+; MPTP; Parkinson's disease; Rasagiline; Selegiline; TVP 1012

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING); AMPHETAMINE; METHAMPHETAMINE; MONOAMINE OXIDASE INHIBITOR; RASAGILINE; SELEGILINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; INDAN DERIVATIVE; NORADRENALIN; SEROTONIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SIZE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; HISTOPATHOLOGY; INJECTION; MALE; MONKEY; MOTOR ACTIVITY; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PARKINSONISM; PRIMATE; PRIORITY JOURNAL; SPECIES DIFFERENCE; ANIMAL; BODY WEIGHT; CHEMISTRY; COMPARATIVE STUDY; DISEASE MODEL; ENZYMOLOGY; IMMUNOHISTOCHEMISTRY; MARMOSET; METABOLISM; NEOSTRIATUM; NERVE CELL; PATHOPHYSIOLOGY; PHYSIOLOGY; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BODY WEIGHT; CALLITHRIX; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; FEMALE; IMMUNOHISTOCHEMISTRY; INDANS; MALE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; NEOSTRIATUM; NEURONS; NOREPINEPHRINE; PARKINSONIAN DISORDERS; SELEGILINE; SEROTONIN; SUBSTANTIA NIGRA;

EID: 0034871806     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (110)

1. Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: Behavioural, morphological and biochemical correlates
2. Increased life expectancy resulting from the addition of L-deprenyl to Madopar treatment in Parkinson's disease: A long-term study
3. A primate model of parkinsonism: Selective destruction of dopaminergic neuons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Proc Natl Acad Sci USA
4. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system of the rat
5. Metabolism of the neurotoxic tertiary amine, MPTP, by monoamine oxidase
6. Formation and clearance of interstitial metabolites of dopamine and serotonin in the rat striatum: An in vivo microdialysis study
7. Chronic parkinsonism secondary to intravenous injection of meperidine analogues
8. The neuronal and extraneuronal origins of plasma 3-methoxy-4-hydroxyphenylglycol in rats
9. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B
10. Pharmacology and neuroprotective properties of rasagline
11. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor
12. Similarities and differences between MPTP-induced Parkinsonism and Parkinson's disease. Neuropathological considerations
13. Inhibition of monoamine oxidase B in the brains of smokers
14. Inhibition of types A and B monoamine oxidase by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
15. A high dose of MPTP overcomes the protective effect of selegiline against dopaminergic neurotoxicity
16. Actions of MPTP and MPP3 on synaptic transmission in guinea pig hippocampal slices
17. Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man
18. MPTP mechanisms of neuro-toxicity and their implications for Parkinson's disease
19. The molecular pharmacology of L-deprenyl
20. New horizons in molecular mechanisms underlying Parkinson's diesease and in our understanding of the neuroprotective effects of selegiline
21. Effect of adding selegiline to levodopa in early, mild Parkinson's disease: On treatment analysis rather than intention to treat analysis should have been used
22. Acute MPTP treatment produces no changes in mitochondrial complex activities and indices of oxidative damage in the common marmoset ex vivo one week after exposure to the toxin
23. High dose selegiline augments striatal ubiquinol in mouse: An indication of decreased oxidative stress or of interference with mitochondrial respiration? A pilot study
24. Monoamine oxidase A and B activities in common marmosets brain: Effects of rasagiline
25. Effects of deprenyl on monoamine oxidase and neuro-transmitters in the brains of MPTP-treated aging mice
26. Stable Parkinsonian syndrome and uneven loss of dopaminefibres following chronic MPTP administration in baboons
27. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors
28. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN 1135, selective inhibitors of nomoamine oxidase-B
29. Studies on the oxidation of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase B
30. Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: Relevance to DATATOP
31. + within the monoaminergic system of the primate brain following MPTP administration: An in vivo autoradiographic study
32. Elevated expression of glutathione peroxidase in PC12 cells results in protection against methamphetamine but not MPTP toxicity
33. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse
34. 2
35. Nigrostriatal monoamine oxidase A and B in aging squirrel monkeys and C57B1 mice
36. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3-6-tetrahydropyridine
37. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset
38. Selective acetylenic "suicide" and reversible inhibitors of monoamine oxidase types A and B
39. Metabolism of (-)-deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: A biochemical assessment
40. Effect of selegiline on dopamine concentration in the striatum of a primate
41. Injury of nigral neurons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A tyrosine hydroxylase immunocytochemical study in monkey
42. Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes
43. (-)Deprenyl (Selegiline): Past, present and future
44. Do NMDA receptor antagonists protect against MPTP toxicity? Biochemical and immunocytochemical analyses in a mouse model of Parkinson's disease
45. N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in hon-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level
46. Role of monamine oxidase type A and B on the dopamine metabolism in discrete regions of the primate brain
47. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo
48. Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo
49. The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates
50. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis
51. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey
52. Pargyline prevents MPTP-induced parkinsonism in primates
53. (-)-Deprenyl protection of 1 methyl-4-phenylpyridium ion (MPP3)-induced apoptosis independent of MAO-B inhibition
54. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease
55. Selective suppression of type B monoamine oxidase immunoreactivity in the raphe nuclei following MPTP administration in the cat
56. Neuroprotective and neuronal rescue effects of selegiline: Review
57. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl, a selective monoamine oxidase inhibitor
58. Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline
59. Parkinson's disease
60. 1-Methyl-4-phenylpyridinium (MPP3) binds with high affinity to a betacarboline binding site located on monoamine oxidase type A in rat brain
61. L-methamphetamine pharmacokinetics and pharmacodynamics for assessment of in vivo deprenyl-derived 1-methamphetamine
62. Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion
63. L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro
64. L-Deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro
65. The effect of deprenyl and levodopa on the progression of Parkinson's disease
66. Effect of selegiline on mortality in patients with Parkinson's disease
67. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
68. Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in common marmosets
69. SELEDO: A 5-year long-term trial on the effect of selegiline in early parkinsonian patients treated with levodopa
70. 1-Deprenyl in atypical depressives
71. Deprenyl is metabolized to methamphetamine and amphetamine in man
72. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with 1-deprenyl
73. Deprenyl induces the tyrosine hydroxylase enzyme in the dopaminergic nigrostriatal system
74. Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP
75. Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets
76. The effects of 1-deprenyl treatment and combined with GM1 ganglioside, on striatal dopamine content and substantia nigra pars compacta neurons
77. Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide incactivation of the enzymes by MPTP
78. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study
79. Attenuation of 1-methyl-4-phenylpyridinium (MPP3) neurotoxicity by deprenyl by deprenyl in organotypic canine substantia nigra cultures
80. Effects of graft pooling of foetal rat and mouse tissue and immunosuppression in the 6-hydroxydopamine rat model of Parkinson's disease
81. Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage
82. Dose-dependent destruction of the coeruleus-cortical and the nigro-striatal projections by MPTP
83. Deprenyl rescues dopaminergic neurons in organotypic slice cultures of neonatal mesencephalon from N-methyl-D-aspartate toxicity
84. DATATOP: A decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of parkinsonism
85. Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat
86. Effects of N-propargyl-1-(R)aminoidan (rasagiline) models of motor and cognition disorders
87. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat
88. Methamphetamine pretreatment and the vulnerability of the striatum to methamphetamine neurotoxicity
89. (R)(-)-N-propargyl-1-aminoindan (rasagiline) and derivatives: Highly selective and potent inhibitors of monoamine oxidase B
90. High-dose selegiline in treatment-resistant older depressive patients
91. Comparison of key steps in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in
92. Amphetamine-metabolites of deprenyl involved in protection against neurotoxicity induced by MPTP and 23-methyl-MPTP
93. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-Deprenyl-related compounds in controlling neurodegeneration
94. MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells
95. The assay of monoamino oxidase
96. The biochemical assay for monoamine oxidase activity. Problems and pitfalls
97. Effect of MPTP and 1-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain
98. L-Deprenyl and MDL 72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse
99. Effect of the MAOB inhibitor, MDL 72974, on superoxide dismutase acitivity and lipid peroxidation levels in the mouse brain
100. Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease
101. Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin
102. Evaluation of the effects of inhibition of monoamine oxidase and senescence on methamphetamine-induced neuronal damage
103. Selegiline stimulates biosynthesis of cytokines interleukin-1 beta and interleukin-6
104. Monoamine oxidase activity and distribution in the marmoset brain, implications for MPTP-toxicity
105. Antioxidant mechanism and protection of nigral neurons against MPP3 toxicity by deprenyl (selegiline)
106. A sensitive and specific assay for the estimation of monoamine oxidase
107. Are metabolites of 1-deprenyl (selegiline) useful or harmful. Indications from preclinical research
108. Neurochemical, neuroprotective and neurorescue effects of aliphatic N-methylpropargylamines; new MAO-B inhibitors without amphetamine-like properties
109. MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates